- Home
- Primary Care
- Cardiovascular Risk Reduction with Ezetimibe Monotherapy in Elderly Patients: Insights from the EWTOPIA 75 Trial

1d3 min read
Medical Article
Introduction: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide, with risk rising sharply in advanced age (1,2). Individuals aged 75 years and older represent one of the fastest-growing populations globally, yet they remain underrepresented in cardiovascular prevention trials (1). Statins

Cardiovascular Risk Reduction with Ezetimibe Monotherapy in Elderly Patients: Insights from the EWTOPIA 75 Trial
Similar Content

Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes

Patient with History of Atrial Fibrillation
519 Reached3 Likes